Arriola Aperribay, EdurneDe Castro, JavierGarcía-Campelo, RosarioBernárdez, BeatrizBernabé, ReyesBruna, JordiDómine, ManuelIsla, DoloresJuan Vidal, ÓscarLópez-Fernández, TeresaNadal, ErnestRodríguez-Abreu, DelvysVares, MaríaAsensio, ÚrsulaGarcía, Luis F.Felip, Enriqueta2025-04-112025-04-112024Arriola E, de Castro J, García-Campelo R, Bernárdez B, Bernabé R, Bruna J, et al. Expert consensus on the management of adverse events of Lorlatinib in the treatment of ALK+ advanced non-small cell lung cancer. Clin Drug Investig. 2024 Aug;44(8):553-76. DOI: 10.1007/s40261-024-01379-71173-2563http://hdl.handle.net/10230/70131The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts.application/pdfeng© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Pulmons--Càncerinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1007/s40261-024-01379-7info:eu-repo/semantics/openAccess